{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:57:44Z","timestamp":1790859464063,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Student Research Committee, Kerman University of Medical Sciences","award":["400000650"],"award-info":[{"award-number":["400000650"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10675-0","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:05:49Z","timestamp":1749542749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined effects of IRAK inhibition and pioglitazone on hepatic inflammation and apoptosis in a mouse model of MASLD"],"prefix":"10.1007","volume":"52","author":[{"given":"Hossein","family":"Fallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Danesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8758-6686","authenticated-orcid":false,"given":"Beydolah","family":"Shahouzehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"2","key":"10675_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/cells14020077","volume":"14","author":"R Weiskirchen","year":"2025","unstructured":"Weiskirchen R (2025) Topic signaling pathways. Liver Disease Cells 14(2):77. https:\/\/doi.org\/10.3390\/cells14020077","journal-title":"Liver Disease Cells"},{"key":"10675_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","volume":"136","author":"KH Liss","year":"2017","unstructured":"Liss KH, Finck BN (2017) PPARs and nonalcoholic fatty liver disease. Biochimie 136:65\u201374. https:\/\/doi.org\/10.1016\/j.biochi.2016.11.009","journal-title":"Biochimie"},{"issue":"1","key":"10675_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","volume":"7","author":"X Xu","year":"2022","unstructured":"Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J (2022) Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH). Signal Transduct Target Ther 7(1):287. https:\/\/doi.org\/10.1038\/s41392-022-01119-3","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10675_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/labinvest.3700489","volume":"87","author":"IA Leclercq","year":"2007","unstructured":"Leclercq IA, Lebrun VA, St\u00e4rkel P, Horsmans YJ (2007) Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist Pioglitazone. Lab Invest 87(1):56\u201365. https:\/\/doi.org\/10.1038\/labinvest.3700489","journal-title":"Lab Invest"},{"issue":"70","key":"10675_CR5","doi-asserted-by":"publisher","first-page":"33416","DOI":"10.18632\/oncotarget.26058","volume":"9","author":"JW Singer","year":"2018","unstructured":"Singer JW, Fleischman A, Al-Fayoumi S, Mascarenhas JO, Yu Q, Agarwal A (2018) Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget 9(70):33416\u201333439. https:\/\/doi.org\/10.18632\/oncotarget.26058","journal-title":"Oncotarget"},{"key":"10675_CR6","doi-asserted-by":"publisher","first-page":"1497095","DOI":"10.3389\/fimmu.2025.1497095","volume":"10","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Wang J, Li H, Niu Q, Tao Y, Zhao X, Zeng Z, Dong H (2025) The role of the Interleukin family in liver fibrosis. Front Immunol 10:16: 1497095. https:\/\/doi.org\/10.3389\/fimmu.2025.1497095","journal-title":"Front Immunol"},{"key":"10675_CR7","doi-asserted-by":"publisher","unstructured":"Shi M, Deng Y, Yu H, Xu L, Shi C, Chen J, Li G, Du Y, Wang YG (2019) Protective effects of oridonin on acute liver injury via impeding posttranslational modifications of interleukin-1 receptor-associated kinase 4 (IRAK4) in the toll-like receptor 4 (TLR4) signaling pathway. Mediators Inflamm 2019:7634761. https:\/\/doi.org\/10.1155\/2019\/7634761","DOI":"10.1155\/2019\/7634761"},{"issue":"8","key":"10675_CR8","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.3390\/ijms23084305","volume":"23","author":"NF Lange","year":"2022","unstructured":"Lange NF, Graf V, Caussy C, Dufour JF (2022) PPAR-Targeted therapies in the treatment of Non-Alcoholic fatty liver disease in diabetic patients. Int J Mol Sci 23(8):4305. https:\/\/doi.org\/10.3390\/ijms23084305","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10675_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","volume":"17","author":"D Ferguson","year":"2021","unstructured":"Ferguson D, Finck BN (2021) Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 17(8):484\u2013495. https:\/\/doi.org\/10.1038\/s41574-021-00507-z","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10675_CR10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gut.2005.079194","volume":"55","author":"IA Leclercq","year":"2006","unstructured":"Leclercq IA, Sempoux C, St\u00e4rkel P, Horsmans Y (2006) Limited therapeutic efficacy of Pioglitazone on progression of hepatic fibrosis in rats. Gut 55(7):1020\u20131029. https:\/\/doi.org\/10.1136\/gut.2005.079194","journal-title":"Gut"},{"key":"10675_CR11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/bcpt.13190","volume":"124","author":"J Skat-R\u00f8rdam","year":"2019","unstructured":"Skat-R\u00f8rdam J, H\u00f8jland Ipsen D, Lykkesfeldt J, Tveden-Nyborg P (2019) A role of peroxisome proliferator-activated receptor \u03b3 in non-alcoholic fatty liver disease. Basic Clin Pharmacol Toxicol 124:528\u2013537. https:\/\/doi.org\/10.1111\/bcpt.13190","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"10675_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1745-7254.2006.00299.x","volume":"27","author":"K Sun","year":"2006","unstructured":"Sun K, Wang Q, Huang XH (2006) PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin 27(6):715\u2013723. https:\/\/doi.org\/10.1111\/j.1745-7254.2006.00299.x","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"10675_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.hepres.2005.05.008","volume":"32","author":"H Uto","year":"2005","unstructured":"Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, Numata M, Nagata K, Hayashi K, Tsubouchi H (2005) The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. Hepatol Res 32(4):235\u2013242. https:\/\/doi.org\/10.1016\/j.hepres.2005.05.008","journal-title":"Hepatol Res"},{"issue":"9","key":"10675_CR14","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.clnu.2024.08.007","volume":"43","author":"G Neira","year":"2024","unstructured":"Neira G, Becerril S, Valent\u00ed V, Moncada R, Catal\u00e1n V, G\u00f3mez-Ambrosi J et al (2024) FNDC4 reduces hepatocyte inflammatory cell death via AMPK\u03b1 in metabolic dysfunction-associated steatotic liver disease. Clin Nutr 43(9):2221\u20132233. https:\/\/doi.org\/10.1016\/j.clnu.2024.08.007","journal-title":"Clin Nutr"},{"issue":"1","key":"10675_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cts.12839","volume":"14","author":"SL Attia","year":"2021","unstructured":"Attia SL, Softic S, Mouzaki M (2021) Evolving role for pharmacotherapy in NAFLD\/NASH. Clin Transl Sci 14(1):11\u201319. https:\/\/doi.org\/10.1111\/cts.12839","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10675_CR16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/cells9071638","volume":"9","author":"A Fougerat","year":"2020","unstructured":"Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W (2020) Peroxisome Proliferator-Activated receptors and their novel ligands as candidates for the treatment of Non-Alcoholic fatty liver disease. Cells 9(7):1638. https:\/\/doi.org\/10.3390\/cells9071638","journal-title":"Cells"},{"key":"10675_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","volume":"24","author":"GW Rhyasen","year":"2013","unstructured":"Rhyasen GW, Bolanos L, Fang J et al (2013) Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24:90\u2013104","journal-title":"Cancer Cell"},{"key":"10675_CR18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/1074248411431581","volume":"17","author":"RA Elrashidy","year":"2012","unstructured":"Elrashidy RA, Asker ME, Mohamed HE (2012) Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther 17:324\u2013333","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10675_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/978-1-61779-430-8_27","volume":"821","author":"CY Wang","year":"2012","unstructured":"Wang CY, Liao JK (2012) A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol 821:421\u2013433","journal-title":"Methods Mol Biol"},{"issue":"7","key":"10675_CR20","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M et al (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol 18(7):e3000410. https:\/\/doi.org\/10.1371\/journal.pbio.3000410","journal-title":"PLoS Biol"},{"issue":"2","key":"10675_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00210-023-02644-w","volume":"397","author":"MR Naiini","year":"2024","unstructured":"Naiini MR, Shahouzehi B, Azizi S, Shafiei B, Nazari-Robati M (2024) Trehalose-induced SIRT1\/AMPK activation regulates SREBP-1c\/PPAR-\u03b1 to alleviate lipid accumulation in aged liver. Naunyn Schmiedebergs Arch Pharmacol 397(2):1061\u20131070. https:\/\/doi.org\/10.1007\/s00210-023-02644-w","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10675_CR22","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.62110\/sciencein.cbl.2025.v12.1256","volume":"12","author":"B Shahouzehi","year":"2024","unstructured":"Shahouzehi B, Masoumi-Ardakani Y, Aminizadeh S (2024) Investigating the effect of calcitonin Gene-Related peptide antagonist and exercise trainings in rat aorta: mitophagy, mitochondrial biogenesis, and apoptosis. Chem Biol Lett 12(1):1256. https:\/\/doi.org\/10.62110\/sciencein.cbl.2025.v12.1256","journal-title":"Chem Biol Lett"},{"issue":"3","key":"10675_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Lefebvre P, Staels B (2015) Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol 62(3):720\u2013733. https:\/\/doi.org\/10.1016\/j.jhep.2014.10.039","journal-title":"J Hepatol"},{"key":"10675_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.37349\/emed.2020.0001","volume":"1","author":"C Acierno","year":"2020","unstructured":"Acierno C, Caturano A, Pafundi PC, Nevola R, Adinolfi LE, Sasso FC (2020) Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Explor Med 1:287\u2013306. https:\/\/doi.org\/10.37349\/emed.2020.0001","journal-title":"Explor Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10675-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10675-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10675-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:28:29Z","timestamp":1766852909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10675-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10675"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10675-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal procedure was approved by the guidelines of the Animal Care Committee of the Ethics Committee of Kerman University of Medical Sciences (IR.KMU.REC.1400.518). All methods were performed in accordance with the ARRIVE (Animal Research: Reporting of in Vivo Experiments) guidelines 2.0.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"576"}}